Management of Severe Thrombocytosis

Diagnostic Considerations

Evaluation for underlying causes of thrombocytosis should include checking for signs of infection or inflammation and assessing for iron deficiency, as recommended by the American Thoracic Society 1
Screening for malignancy based on age and risk factors is also necessary, according to the National Comprehensive Cancer Network 2

For primary thrombocytosis, cytoreductive therapy is indicated for high-risk patients, and hydroxyurea is the first-line treatment for patients with essential thrombocythemia at high risk of thrombotic complications, as recommended by the National Comprehensive Cancer Network 2
Low-dose aspirin should be administered if microvascular disturbances are present, as suggested by the National Comprehensive Cancer Network 2
For secondary thrombocytosis, treatment should focus on the underlying cause rather than the platelet count itself, and cytoreductive therapy is generally not indicated unless platelet count exceeds 1,500 × 10^9/L, as recommended by the National Comprehensive Cancer Network 2
Antiplatelet therapy is not routinely recommended for secondary thrombocytosis without other risk factors for thrombosis, according to the American Thoracic Society 1

If the patient requires anticoagulation, full-dose anticoagulation is considered safe with platelet counts >50 × 10^9/L, as recommended by the International Society on Thrombosis and Haemostasis 3
For patients with cancer-associated thrombosis, platelet counts >50 × 10^9/L allow for full therapeutic anticoagulation, according to the International Society on Thrombosis and Haemostasis 3 and 4
Secondary thrombocytosis in children is generally benign and self-limiting, with no specific treatment required in most cases, as suggested by the American Thoracic Society 1

For primary thrombocytosis, response to therapy should be evaluated by normalization of blood counts and resolution of symptoms, as recommended by the National Comprehensive Cancer Network 2